Paxalisib: Beyond glioblastoma and commercial opportunity

Paxalisib: Beyond glioblastoma and commercial opportunity

Kazia Therapeutics — 9 videos in collection

More on this equity

In the second part of this three-episode Edison TV series, Kazia Therapeutics (KZIA), dives deeper into paxalisib for additional indications beyond glioblastoma. These indications include DIPG, a highly aggressive childhood brain cancer, primary CNS lymphoma, and brain metastases.

John Friend, CMO, discusses ongoing investigator-initiated trials and collaborations. James Garner, CEO, addresses commercialisation plans.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free